Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Queensland Health
Covington
Medtronic
Moodys

Generated: September 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,410,167

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,410,167 protect, and when does it expire?

Patent 8,410,167 protects MULTAQ and is included in one NDA.

This patent has fifty-five patent family members in twenty-seven countries.

Summary for Patent: 8,410,167
Title:Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
Abstract: Methods of using dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality, articles of manufacture and packages related thereto.
Inventor(s): Radzik; Davide (Paris, FR), Van Eickels; Martin (Berlin, DE), Hamdani; Nacera (Paris, FR), Gaudin; Christophe (Paris, FR)
Assignee: SANOFI (Paris, FR)
Application Number:12/425,125
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,410,167
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,410,167

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sanofi Aventis Us MULTAQ dronedarone hydrochloride TABLET;ORAL 022425-001 Jul 1, 2009 RX Yes Yes   Try a Free Trial   Try a Free Trial TREATMENT OF PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS   Try a Free Trial
Sanofi Aventis Us MULTAQ dronedarone hydrochloride TABLET;ORAL 022425-001 Jul 1, 2009 RX Yes Yes   Try a Free Trial   Try a Free Trial REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,410,167

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France08 02127Apr 17, 2008
France08 03208Jun 10, 2008
09290095Feb 11, 2009
09290098Feb 11, 2009

International Family Members for US Patent 8,410,167

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 072950   Try a Free Trial
Argentina 072951   Try a Free Trial
Australia 2009252897   Try a Free Trial
Australia 2009252898   Try a Free Trial
Brazil PI0910631   Try a Free Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Cipla
Teva
US Army
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.